Paolisso et al. reported that diabetic patients treated with SGLT2 inhibitors before acute myocardial infarction had significantly lower in-hospital mortality and lower incidence of arrhythmic events and acute kidney injury after percutaneous coronary intervention11. This evidence concerns the gene SLC5A2 and acute myocardial infarction.